CA2346825C - Procede de production d'hemoglobine exempte de stroma - Google Patents
Procede de production d'hemoglobine exempte de stroma Download PDFInfo
- Publication number
- CA2346825C CA2346825C CA002346825A CA2346825A CA2346825C CA 2346825 C CA2346825 C CA 2346825C CA 002346825 A CA002346825 A CA 002346825A CA 2346825 A CA2346825 A CA 2346825A CA 2346825 C CA2346825 C CA 2346825C
- Authority
- CA
- Canada
- Prior art keywords
- solution
- hemolysate
- blood cells
- red blood
- hemoglobin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010001708 stroma free hemoglobin Proteins 0.000 title abstract description 31
- 238000004519 manufacturing process Methods 0.000 title description 15
- 238000000034 method Methods 0.000 claims abstract description 86
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 83
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 83
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 77
- 238000012545 processing Methods 0.000 claims abstract description 67
- 210000004027 cell Anatomy 0.000 claims abstract description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 77
- 210000002381 plasma Anatomy 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 13
- 230000002934 lysing effect Effects 0.000 claims description 11
- 239000000815 hypotonic solution Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 75
- 239000008280 blood Substances 0.000 abstract description 75
- 239000003633 blood substitute Substances 0.000 abstract description 25
- 230000008569 process Effects 0.000 abstract description 17
- 239000000306 component Substances 0.000 abstract description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 13
- 239000001301 oxygen Substances 0.000 abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 abstract description 13
- 239000002994 raw material Substances 0.000 abstract description 9
- 210000000601 blood cell Anatomy 0.000 abstract description 7
- 239000000969 carrier Substances 0.000 abstract description 5
- 230000036512 infertility Effects 0.000 abstract description 5
- 239000012503 blood component Substances 0.000 abstract description 4
- 239000012467 final product Substances 0.000 abstract description 4
- 230000035939 shock Effects 0.000 abstract description 4
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 238000011065 in-situ storage Methods 0.000 abstract description 3
- 239000006166 lysate Substances 0.000 abstract description 3
- 238000002955 isolation Methods 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 10
- 238000011109 contamination Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000009089 cytolysis Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 108010061951 Methemoglobin Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000003278 haem Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000012953 feeding on blood of other organism Effects 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 108010036302 hemoglobin AS Proteins 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 1
- 244000202285 Acrocomia mexicana Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 241000239217 Limulidae Species 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010031004 PEG-hemoglobin Proteins 0.000 description 1
- 208000031306 Rare hereditary hemochromatosis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 238000007727 cost benefit analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000007817 turbidimetric assay Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
- A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
- A61M1/3698—Expressing processed fluid out from the turning rotor using another fluid compressing the treatment chamber; Variable volume rotors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
- A61M2202/0433—Free haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
- A61M2205/331—Optical measuring means used as turbidity change detectors, e.g. for priming-blood or plasma-hemoglubine-interface detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3317—Electromagnetic, inductive or dielectric measuring means
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Centrifugal Separators (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne un procédé employant un séparateur de cellules sanguines disponible sur le marché, qui comporte une centrifugeuse (2) commandée par ordinateur et pourvue d'un rotor (24) dans lequel on place un sac (6) de traitement de sang contenant du sang de donneur. Après prélèvement du sang, le procédé est mis en oeuvre entièrement à l'intérieur du bol de centrifugeuse fermé, de préférence in situ au site de transfusion. Au cours d'une première étape, le sang est centrifugé en vue de séparer le plasma des constituants cellulaires. Après isolement des globules rouges des autres constituants sanguins, les globules rouges sont lavés à l'aide d'une solution saline normale ou d'une autre solution. Les globules rouges sanguins sont ensuite lysés par choc hypotonique pour séparer les membranes des globules rouges (stroma), et le lysat est recueilli dans un contenant stérile (44), seul le stroma restant dans le bol de centrifugeuse. Le produit final peut être utilisé comme matière première pour tout transporteur d'oxygène à base d'hémoglobine actuellement mis au point comme substitut de globules rouges. Toutes les étapes sont mises en oeuvre à l'intérieur d'un contenant de traitement ou sac de sang (6) dans la centrifugeuse à bol pour réduire au minimum les manipulations et maintenir la stérilité. L'invention concerne un procédé de préparation d'une solution d'hémoglobine modifiée, qui incorpore les étapes permettant de produire de l'hémoglobine exempte de stroma, une étape ultérieure d'ajout de réactifs mesurés au préalable en vue d'une réaction avec la solution, et un filtrage de la solution.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10431998P | 1998-10-15 | 1998-10-15 | |
| US60/104,319 | 1998-10-15 | ||
| US12218099P | 1999-03-01 | 1999-03-01 | |
| US60/122,180 | 1999-03-01 | ||
| PCT/US1999/024149 WO2000021591A1 (fr) | 1998-10-15 | 1999-10-15 | Procede de production d'hemoglobine exempte de stroma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2346825A1 CA2346825A1 (fr) | 2000-04-20 |
| CA2346825C true CA2346825C (fr) | 2008-07-29 |
Family
ID=26801402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002346825A Expired - Fee Related CA2346825C (fr) | 1998-10-15 | 1999-10-15 | Procede de production d'hemoglobine exempte de stroma |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1121165A1 (fr) |
| JP (1) | JP2002527149A (fr) |
| KR (1) | KR20010099700A (fr) |
| CN (1) | CN1332646A (fr) |
| AU (1) | AU771465B2 (fr) |
| BR (1) | BR9915734A (fr) |
| CA (1) | CA2346825C (fr) |
| MX (1) | MXPA01003836A (fr) |
| WO (1) | WO2000021591A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025141530A1 (fr) * | 2023-12-29 | 2025-07-03 | Lifefactors Canadá (Lifefactors Ip Lp) | Système de séparation de composants plasmatiques par décongélation contrôlée au moyen de mécanismes intégrés de transfert thermique contrôlé et sédimentation accélérée dans des moyens continus |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080138790A1 (en) * | 2004-04-13 | 2008-06-12 | Winslow Robert M | Methods and Compositions for Simultaneously Isolating Hemoglobin from Red Blood Cells and Inactivating Viruses |
| JP2006021121A (ja) | 2004-07-08 | 2006-01-26 | Hitachi Koki Co Ltd | 遠心分離機 |
| ITLU20070013A1 (it) * | 2007-06-22 | 2008-12-23 | Kedrion Spa | Processo per la purificazione di emoglobina umana apirogena e virus inattivata. |
| WO2009072003A2 (fr) * | 2007-12-07 | 2009-06-11 | Miltenyi Biotec Gmbh | Système et procédés de traitement d'échantillons |
| CA2791122C (fr) * | 2010-02-25 | 2019-08-27 | Sangart, Inc. | Procedes de preparation de conjugues peg-hemoglobine utilisant des rapports reduits de reactif |
| JP2015536719A (ja) * | 2012-11-05 | 2015-12-24 | ヘモネティクス・コーポレーションＨａｅｍｏｎｅｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ | 全血の連続分離のためのシステム及び方法 |
| CN103091149B (zh) * | 2013-01-10 | 2015-08-05 | 济南金域医学检验中心有限公司 | 血红蛋白电泳液的制备方法 |
| EP2961760B1 (fr) | 2013-02-26 | 2021-03-24 | EMD Millipore Corporation | Extraction sélective d'une protéine contenue dans un mélange de protéines au moyen de charbon actif par ajustement des conditions de la solution. |
| CN114225072B (zh) * | 2014-04-15 | 2024-01-02 | 勃林格殷格翰国际公司 | 在制造生物制品期间连续灭活病毒的方法、装置和系统 |
| EP3759208A1 (fr) * | 2018-03-02 | 2021-01-06 | Thermo Electron LED GmbH | Récipients de centrifugeuse à usage unique pour séparer des suspensions biologiques et procédés d'utilisation |
| CN109298171B (zh) * | 2018-11-15 | 2022-06-28 | 武汉中生毓晋生物医药有限责任公司 | 醛化红细胞中内毒素的去除方法与应用 |
| CN119746044A (zh) * | 2025-03-06 | 2025-04-04 | 润方（北京）生物医药研究院有限公司 | 血红蛋白氧载体在制备抗病毒药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4303193A (en) | 1979-01-22 | 1981-12-01 | Haemonetics Corporation | Apparatus for separating blood into components thereof |
| US4401652A (en) * | 1980-12-31 | 1983-08-30 | Allied Corporation | Process for the preparation of stroma-free hemoglobin solutions |
| US5464814A (en) * | 1986-06-20 | 1995-11-07 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| CA1312009C (fr) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Substitut sanguin semi-synthetique extra pur |
| JPH02121931A (ja) * | 1988-10-29 | 1990-05-09 | Res Inst For Prod Dev | 濃縮ヘモグロビンの製造方法 |
| US5646252A (en) * | 1992-02-10 | 1997-07-08 | Staat Der Nederlanden, De Minister Van Defensie, Voor Deze: Het Hoofd Van De Afdeling Militair Geneeskundig Beleid | Hemoglobin composition and preparation thereof |
| US5676644A (en) | 1995-06-07 | 1997-10-14 | Cobe Laboratories, Inc. | Extracorporeal blood processing methods and apparatus |
| US5814601A (en) | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
-
1999
- 1999-10-15 CN CN99813429A patent/CN1332646A/zh active Pending
- 1999-10-15 CA CA002346825A patent/CA2346825C/fr not_active Expired - Fee Related
- 1999-10-15 BR BR9915734-9A patent/BR9915734A/pt not_active IP Right Cessation
- 1999-10-15 KR KR1020017004781A patent/KR20010099700A/ko not_active Withdrawn
- 1999-10-15 EP EP99954950A patent/EP1121165A1/fr not_active Withdrawn
- 1999-10-15 MX MXPA01003836A patent/MXPA01003836A/es unknown
- 1999-10-15 WO PCT/US1999/024149 patent/WO2000021591A1/fr not_active Ceased
- 1999-10-15 AU AU11170/00A patent/AU771465B2/en not_active Ceased
- 1999-10-15 JP JP2000575563A patent/JP2002527149A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025141530A1 (fr) * | 2023-12-29 | 2025-07-03 | Lifefactors Canadá (Lifefactors Ip Lp) | Système de séparation de composants plasmatiques par décongélation contrôlée au moyen de mécanismes intégrés de transfert thermique contrôlé et sédimentation accélérée dans des moyens continus |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002527149A (ja) | 2002-08-27 |
| WO2000021591A1 (fr) | 2000-04-20 |
| BR9915734A (pt) | 2001-10-02 |
| KR20010099700A (ko) | 2001-11-09 |
| CN1332646A (zh) | 2002-01-23 |
| AU771465B2 (en) | 2004-03-25 |
| AU1117000A (en) | 2000-05-01 |
| CA2346825A1 (fr) | 2000-04-20 |
| MXPA01003836A (es) | 2002-09-18 |
| EP1121165A1 (fr) | 2001-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1312009C (fr) | Substitut sanguin semi-synthetique extra pur | |
| CA2346825C (fr) | Procede de production d'hemoglobine exempte de stroma | |
| US9480786B2 (en) | Component preparation system | |
| CA2035929C (fr) | Filtration pre-stockage des plaquettes sanguines | |
| AU753536B2 (en) | Systems and methods for processing and storing placenta/umbilical cord blood | |
| CA2434317C (fr) | Systemes et procedes de traitement manuel permettant de fournir des constituants sanguins conditionnes en vue de l'inactivation pathogene | |
| JP2962731B2 (ja) | 超純枠半合成代用血液 | |
| US20020082153A1 (en) | Blood component preparation (BCP) device and method of use thereof | |
| US6773613B1 (en) | Method for production of stroma-free hemoglobin | |
| MXPA06006940A (es) | Sistemas y metodos de procesamiento para proporcionar componentes sanguineos reducidos en leucocitos acondicionados para inactivacion de patogenos. | |
| US20020020680A1 (en) | Blood component preparation (BCP) device and method of use thereof | |
| CN108135936A (zh) | 冷沉淀物组合物及其制备方法 | |
| US5589389A (en) | Apparatus for causing medicinal products to penetrate into red blood cells | |
| WO2001097943A1 (fr) | Dispositif de preparation des composants sanguins et procede d'utilisation dudit dispositif | |
| Hardwick et al. | Blood processing and components | |
| US20250188425A1 (en) | Additive Solution for Erythrocyte Concentrates | |
| Loos et al. | Leukocyte depletion: a biotechnical transfusion story | |
| Rebulla et al. | The manual preparation of leukocyte‐poor red cells for transfusion by a new filter | |
| Kurtz et al. | Leukocyte‐poor red blood cells prepared by the addition and removal of glycerol from red blood cell concentrates stores at 4 C | |
| JPS59501344A (ja) | 増加収量連続流血液成分採取システム | |
| Ciavarella | Blood processors and cell separators | |
| US20240318138A1 (en) | Method and device for preparing universal plasma | |
| Wenz | Leukocyte-poor blood | |
| Norol et al. | Apheresis experience with a continuous flow cell separator | |
| Myhre et al. | Studies on 4 C Stored Frozen‐Reconstituted Red Blood Cells: II. Chemical and Cytological Changes during Storage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |